Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.
nysize, don’t be such a drama queen. i have not wet my knickers etc. it’s a share board for exchanging views. my view is the sp is ****e despite all the great progress. are you happy with 92p?
I take full responsibility for my investment decision. It doesn’t mean I am blind to the crap SP or the bizarre recent comms which seems to be mainly to individual investors. What is happening with C7, the fortnightly trial etc, how many patients have been dosed….?
NYsize you are close minded and lack any objectivity.
The SP is now under the 95p discounted placing in October 2022, when C4 was in progress. The trial news has all been positive, but here we are sitting with an SP sub £1 and an almost daily grind down. Any LTH’s indifferent to that must be bonkers.
PL75,
“It's no different to any other time. They've nothing to update on. The same was true between Aug and Oct last year when the only operational update was the completion of the 6th cohort”.
I don’t agree, I think they DO have something to update on, which at the very least is the formal completion of C7. The current farcical comms means that we have learnt it has been “signed off” via feedback from PI’s who have been in contact touch with AS.. Ditto any news on the fortnightly study.
The have always previously RNS’d the completion of each cohort. They don’t have to release all the data. But I want to hear news direct from the company and not through third parties.
Thorn,
“As far as I'm concerned I don't think Avacta can comment at the moment.
I think a raise is in the offing so they can't say anything until it's in the open.
TW got to hear (as he unfortunately so often does) and put out a Short.
Time will tell.”
I am coming around to that view myself. The current SP decline has the hallmarks of a raise. I hope not, I have tried to average down (unsuccessfully) a lot recently.
Energyshares, well called out with Sheppy and his “small holding” which has miraculously morphed into 500k shares. I laughed so much I almost crashed the Ferrari when I was parking it in my 10 berth garage.
Thanks BV for some very informative posts today.
Like others I find it frustrating that we have to find this information out from posters on this board, rather than directly from the company. I really hope they remedy this soon. In the meantime thank you to those who have shared the replies they have received from AS. It is greatly appreciated.
“The planned Arm 2 dosing levels are 160, 200, 250 and 310. Their equivalents on a 3-weekly study (i.e. same amount after 6 weeks) are 240, 300, 375 and 465. C7 was at 385 with nio MTD, so all Arm 2 cohorts should be good for this simpler dosing regimen all the way.”
Sorry BV, I don’t understand the figures you used for the three weekly equivalents (240, 300, 375 and 465). I listened again to CC’s explanation and I’m still confused.
TG2D, you best contact Crescendo (prostate) & Artios (DDR assay breast/ovarian/prostate) and tell them to cancel their contracts.
Then you better contact all the KOL’s & researchers and advise them their research is invalid unless it is related to MBC.
Sorry RP.
And Tim, I’ve just watched your YouTube clip, it’s hard (“that what she said”) not to have a good laugh at it 😆 I’m going to drive myself and my better half nuts ( that what she said) saying it now.
I agree JT. This is the question that was submitted at the data update presentation.
Question 18.
Now the P1A data has been released, can it still be published in a peer reviewed journal and/or at a major oncology conference. This was Avacta’s original aim but that changed, could you clarify why?
Answer
Yes it can. We have provided a summary of key findings and have more data that we can add to those to secure presentation slots at major conferences in 2024.
Whatever the reason for FM’s departure, it was good to note that “Fiona will continue to work with the Company through a transitionary period”. (RNS)
I think CC’s US experience would also have been a big factor in any boardroom decision making. “Chris brings deep oncology research and development expertise combined with trans-Atlantic C-level experience from which the entire business will benefit as we evolve from a research organisation to one led by a strong clinical focus”.